Evaluating integrated care to improve outcomes for liver transplant patients with alcohol-related liver disease
Official title: 2/4-The INTEGRATE Study: Evaluating INTEGRATEd care to Improve Biopschosocial Outcomes of Early Liver Transplantation for Alcohol-Associated Liver Disease
Funded at Columbia University Health Sciences · NIH-10894076 · Data updated 2026-11-12
This study is looking at how combined medical and support care can help people with alcohol-related liver disease who are getting a liver transplant, focusing on what helps them get referred for the transplant and how they can do better afterward.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2030 |
| Funding year | 2024 |
| Award (this year) | $434,338 |
| NIH project number | 5R01AA030958-02 |
| Project ID | NIH-10894076 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with alcohol-associated liver disease who are being considered for early liver transplantation.
✕Less likely to help
Patients with liver disease not associated with alcohol or those who have already undergone liver transplantation may not benefit from this research.
What this research studies
This research investigates the impact of integrated care on patients undergoing early liver transplantation for alcohol-associated liver disease. It aims to identify factors that influence referrals for early transplantation and develop risk prediction models for patient outcomes. The study will incorporate biopsychosocial measures to better understand how integrated care can support patients in achieving abstinence and improving their post-transplant outcomes. By collaborating with a diverse group of clinicians and researchers, the project seeks to fill knowledge gaps in the treatment of alcohol-related liver disease.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and quality of life for patients undergoing liver transplantation due to alcohol-related liver disease.
How similar studies have gone: Previous studies have shown promising results with integrated care approaches in similar patient populations, indicating potential for success in this research.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Verna, Elizabeth Clarice — Columbia University Health Sciences
- Study coordinator: Verna, Elizabeth Clarice
Related research
Other NIH-funded projects on the same topics.
-
Targeting a specific CD38 form to protect livers from injury after transplant
A new approach tests a selective drug to protect donor livers from injury during transplant, potentially increasing usable organs and improving transplant outcomes.
-
Regulatory dendritic cell therapy to reduce immunosuppressive drugs after liver transplant
A new approach using donor-derived regulatory dendritic cells is being tested to help adults who receive a liver transplant live without relying on traditional immunosuppressive drugs.
-
HOPE liver transplant: reducing infections and cancer risk for HIV-positive recipients
This grant aims to better understand why HIV-positive liver transplant recipients face higher infection and cancer risks and to improve safety and outcomes for these patients.
-
Early liver transplant decisions for severe alcohol-related liver disease
A large study follows adults with severe alcohol-related liver disease to understand how to best select and manage patients for early liver transplantation.
-
Early Liver Transplant for Severe Alcoholic Hepatitis
A hospital-based program is studying whether offering an early liver transplant to patients with severe alcoholic hepatitis can save lives when standard medical treatment fails.
-
Early liver transplant for severe alcoholic hepatitis (SAH) to save lives
A Johns Hopkins program is testing whether giving an early liver transplant to patients with severe alcoholic hepatitis who can’t be helped by standard treatments can save lives and reduce relapse risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.